Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01833806 · ClinicalTrials.gov registry record · NA
A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
A NA study, sponsored by InSightec.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT01833806 is a NA study that has completed, run by InSightec. The registered enrollment target is 32 participants.
The verdict
NCT01833806, a NA study, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The study hypotheses is that the proportion of patients experiencing clinically significant pain relief will be at least 30% greater than the proportion experiencing worsening pain.
Interventions
- DEVICE ExAblate MRgFUS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-09 |
| Est. Completion | 2022-01-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01833806
The ClinicalTrials.gov registry entry for NCT01833806 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ExAblate MRgFUS is the first listed.
NCT01833806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01833806 about?
NCT01833806 is a clinical study titled "A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain". The study hypotheses is that the proportion of patients experiencing clinically significant pain relief will be at least 30% greater than the proportion experiencing worsening pain.
What is the current status of trial NCT01833806?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2013-09. Estimated completion is 2022-01-14.
What interventions are being tested in trial NCT01833806?
The interventions under investigation include: ExAblate MRgFUS (DEVICE).
Who is sponsoring clinical trial NCT01833806?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.